Atara Biotherapeutics
Open
$4.88
Prev. Close
$4.88
High
$4.88
Low
$4.79
Market Snapshot
$33.17M
1.0
-11.75
$128.94M
14
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. The company is headquartered in Thousand Oaks, California. The company went IPO on 2014-10-16. The firm is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
Atara Biotherapeutics investors are alerted about a class action lawsuit by Levi & Korsinsky for losses incurred between May 20, 2024, and January 9, 2026.
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. The company is headquartered in Thousand Oaks, California. The company went IPO on 2014-10-16. The firm is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
Recently from Cashu
Atara Biotherapeutics Faces Class-Action Lawsuits Amid Regulatory Approval Challenges for Tabelecleucel
Atara Biotherapeutics Faces Legal Challenges Amid Regulatory Scrutiny Atara Biotherapeutics, known for its innovative therapies targeting solid tumors and autoimmune diseases, encounters significant l…
Atara Biotherapeutics Faces Class Action Lawsuits Over Regulatory Misstatements Regarding Tabelecleucel
Atara Biotherapeutics Faces Class Action Lawsuits Amid Regulatory Allegations Atara Biotherapeutics, a biopharmaceutical company focused on developing innovative therapies for serious diseases such as…
It seems there was no content provided for me to summarize. Please share the text you'd like summarized.
Please provide the content you'd like me to summarize, and I'll create a 300-500 word article for you.
It seems there was no content provided for me to summarize. Please share the text you'd like summarized, and I will create a title for you.
Please provide the content you would like me to summarize, and I'll create the article for you.